An announcement from Chugai Pharmaceutical Co ( (JP:4519) ) is now available.
Chugai Pharmaceutical Co., Ltd. announced that Eli Lilly’s oral GLP-1 drug, orforglipron, showed statistically significant efficacy and a safety profile consistent with injectable GLP-1 medicines in a Phase 3 trial for type 2 diabetes. The trial results, which will be presented at the ADA’s Scientific Sessions, indicate potential for orforglipron in diabetes management and weight control, with regulatory submissions expected soon. This announcement is not anticipated to affect Chugai’s financial results for the fiscal year ending December 2025.
More about Chugai Pharmaceutical Co
Chugai Pharmaceutical Co., Ltd. is a prominent player in the pharmaceutical industry, focusing on the development and marketing of innovative drugs. The company is known for its contributions to the healthcare sector, particularly in the field of biotechnology and pharmaceuticals, with a strong market presence in Japan and globally.
YTD Price Performance: 8.18%
Average Trading Volume: 8,619
Technical Sentiment Signal: Strong Sell
Current Market Cap: $76.51B
Learn more about 4519 stock on TipRanks’ Stock Analysis page.